Overview
Dravet syndrome (DS) is a serious and uncommon hereditary brain malfunction also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI). It generally starts in the first year of life and lasts the rest of one’s life. Children with dravet syndrome experience a variety of seizures, including myoclonic seizures, tonic-clonic seizures, absence seizures, and atypical convulsions. For the treatment of Dravet syndrome, a mixture of medicines is given. The most widely used medicines for treating seizures and Dravet syndrome include anticonvulsants like stiripentol, topiramate, and Valproic acid. Certain devices are used to treat Dravet syndrome when medicine does not lessen the severity of the seizures.
Request for Analysis of COVID-19 Impact on Dravet Syndrome Treatment Market –
https://www.coherentmarketinsights.com/insight/request-sample/1548
Drivers
Increased research and development initiatives for the creation of innovative Dravet syndrome medications, as well as their subsequent approval in major areas such as North America and Europe, are projected to drive the global Dravet syndrome treatment market forward in the coming years. Epygenix Therapeutics, Inc., a biopharmaceutical firm, acquired orphan drug designation from the U.S. FDA (Food and Drug Administration) in 2017 for its EPX-300, which is used to cure Dravet syndrome.
Moreover, strategic partnerships among major market players for the discovery and production of medicines approved for the treatment of Dravet syndrome are anticipated to fuel growth of the global Dravet syndrome treatment market. Laurus Synthesis Inc. and Epygenix Therapeutics, Inc. formed a strategic partnership in 2017 to develop and produce EPX-100.
Regional Insights
Due to increased activities and financing by various organizations to encourage the development of novel Dravet syndrome treatments, North America is projected to retain a dominating position in the global Dravet syndrome treatment market. The Dravet Syndrome Foundation, a non-profit organization headquartered in the U.S. devoted to supporting high-quality study on Dravet syndrome, awarded a total of US$ 3,600,000 towards the development of innovative Dravet syndrome treatment techniques in 2017.
Along with increased research and development efforts being implemented by major players in the area, the Dravet syndrome treatment market in Europe is projected to expand significantly. Epidiolex was created by GW Pharmaceuticals, a British biopharmaceutical firm, using a marijuana-derived component. In December 2017, the firm submitted an Epidiolex new drug application to the U.S. Food and Drug Administration. Epidiolex is projected to hit the market in the U.S. by the middle of 2018 if the FDA approves it.
Request PDF Brochure Report –
https://www.coherentmarketinsights.com/insight/request-pdf/1548
Restraint
According to a 2015 research published in NCBI, the dravet syndrome affects only around 1 out of every 15,700 people in the United States. The occurrence of dravet syndrome is so low that most people are unaware of it, which is one of the key factors limiting the global Dravet syndrome treatment market’s growth.
Competitive Landscape
Major companies contributing in the global Dravet syndrome treatment market are Takeda Pharmaceutical Company Ltd, GW Pharmaceuticals Plc., Epygenix Therapeutics, Inc., PTC Therapeutics, Inc., Ovid Therapeutics, Biocodex S.A., Biscayne Neurotherapeutics, Inc., OPKO Health Inc., and Zogenix, Inc.
Leading regulatory agencies such as the FDA and the European Commission are concentrating on getting clearance for new medications from key participants in the industry. Biscayne Neurotherapeutics, Inc. acquired Orphan Drug designation from the US Food and Drug Administration in 2017 for its chemical BIS-001, which is used to treat Dravet syndrome.
Reasons to Purchase this Report
Current and future of global Dravet Syndrome Treatment market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Buy This Complete A Business Report With Flat US $2000 Off @
https://www.coherentmarketinsights.com/promo/buynow/1548
Dravet Syndrome Treatment Market Taxonomy:
The global Dravet syndrome treatment market is segmented on the basis of treatment type, distribution channel, and region:
By Treatment Type
- Drugs
- Anticonvulsant
- Benzodiazepines
- Others
- Device
- Vagal Nerve Stimulation
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
View Press Release For More Information
Major Point Answered in Dravet Syndrome Treatment Market Research Study are:
What will be the progress rate of the Dravet Syndrome Treatment Market for the conjecture period, 2020-2027?
What are the prominent factors driving the Dravet Syndrome Treatment Market across different regions?
Who are the major vendors dominating the Dravet Syndrome Treatment industry and what are their winning strategies?
What will be the market scope for the estimated period?
What are the major trends shaping the expansion of the industry in the coming years?
What are the challenges faced by the Dravet Syndrome Treatment Market?
Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
